anayamalik, Author at European Medical Journal - Page 59 of 97

Twice-Yearly Biologic Shows Long-Term Safety in Asthma

A 12-month interim analysis of the AGILE Phase III open-label extension study confirms that twice-yearly depemokimab, an ultra-long-acting anti-IL-5 biologic, maintains a favorable safety and efficacy profile in patients with type 2 asthma.

COVID-19 Booster Protection: How Long Does It Last?

Analysis of over 1.5 million U.S. adults in a new study has found that annual COVID-19 variant-targeted boosters provide meaningful protection against severe disease but lose effectiveness beyond 6 months.

Cancer Outcomes in Rheumatoid Arthritis: Increased Mortality Rates

A recent long-term population study from Western Australia has revealed critical insights into the relationship between rheumatoid arthritis (RA) and cancer outcomes.

Study Finds 99% of Psoriasis Diet Advice on Instagram Is Misinformation

Dietary recommendations for psoriasis on Instagram have been analyzed in a new study, which found that nearly all posts lack scientific credibility, with most advice coming from unqualified individuals.

Positive Survival Outcomes for Melanoma Brain Metastases in New Trial

A phase II trial evaluating the combination of pembrolizumab and bevacizumab in patients with untreated melanoma brain metastases (MBM) has demonstrated substantial clinical activity and promising survival outcomes.

Can AI Diagnose Unexplained Fainting?

A machine-learning classifier designed to assist healthcare professionals in accurately diagnosing the causes of transient loss of consciousness (TLOC) has been introduced in a new study.

Pediatric OSA: How Predictive is CPAP Pressure?

Continuous positive airway pressure (CPAP) therapy is a cornerstone in managing severe obstructive sleep apnea (OSA) in children.

AI Predicts Tuberculosis Risk in HIV: CROI 2025

A machine learning-based model has demonstrated the ability to predict active tuberculosis (TB) in people with HIV (PWH) using clinical data, offering a promising tool for improving early detection and preventive treatment.

Are We Testing the Right Patients for TB? Data from CROI 2025

New data from a 15-year study presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco reveals significant disparities in latent tuberculosis infection (LTBI) testing practices within the United States.

Streamlined Self-Efficacy Measure Enhances ART Outcomes: CROI 2025

A recent study presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco has unveiled a simplified approach to assessing antiretroviral therapy (ART) adherence among pregnant women living with HIV in Malawi.